Welcome to our dedicated page for XOMA Royalty Corporation news (Ticker: XOMA), a resource for investors and traders seeking the latest updates and insights on XOMA Royalty Corporation stock.
XOMA Royalty Corporation (Nasdaq: XOMA) is a biotechnology royalty aggregator that regularly reports on transactions, partner developments, and portfolio evolution. News about XOMA Royalty often centers on its acquisition of royalty and milestone interests in therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies, as well as on corporate events that affect its capital structure and governance.
Recent announcements highlight XOMA Royalty’s completion of acquisitions of companies such as HilleVax, LAVA Therapeutics, Mural Oncology, and Turnstone Biologics, which add partnered programs and associated economic interests to its portfolio. The company also issues updates on strategic royalty-sharing transactions, including amendments to its collaboration with Takeda related to mezagitamab and exposure to a basket of development-stage assets in Takeda’s externalized assets portfolio.
Investors following XOMA Royalty news will see regular disclosures on quarterly and year-to-date financial results, including royalty and milestone receipts from commercial assets like VABYSMO, OJEMDA, MIPLYFFA, XACIATO, IXINITY, and DSUVIA. The company’s releases also summarize key clinical and regulatory milestones reported by its partners, since these events can influence the timing and magnitude of potential royalty and milestone payments.
Additional news items cover preferred stock dividends on the company’s Series A and Series B Cumulative Perpetual Preferred Stock, at-the-market offerings of common and preferred securities, and leadership changes such as transitions in the Chief Financial Officer role. For investors and observers, the XOMA Royalty news feed provides a consolidated view of business development activity, partner pipeline progress, financing decisions, and governance updates that shape the company’s royalty and milestone portfolio over time.
XOMA Corporation (NASDAQ: XOMA) has announced that CEO Jim Neal will present a business update at the Wedbush PacGrow Virtual Healthcare Conference on August 12, 2020, at 3:30 PM ET. The presentation will be live-streamed and accessible through the investor relations section of XOMA's website. An archived version will be available for 90 days post-event. XOMA focuses on licensing programs in biotechnology and pharmaceuticals, aiming to create value through milestone and royalty proceeds from partnered developments.
XOMA Corporation (NASDAQ: XOMA) has appointed Natasha A. Hernday to its Board of Directors. Hernday brings 20 years of corporate development experience, previously serving at Seattle Genetics and Amgen. CEO Jim Neal expressed confidence that Hernday's expertise in asset licensing and partnerships will enhance XOMA's royalty aggregator business model. Hernday is expected to play a pivotal role in advancing the company's strategy focused on human health breakthroughs through royalty aggregation.
XOMA Corporation (Nasdaq: XOMA) has been officially included in the Russell 2000® and Russell 3000® indexes as of June 26, 2020. This inclusion is expected to enhance the Company's visibility among investors and potentially expand its shareholder base, according to CEO Jim Neal. The Russell 3000® Index tracks the largest 3,000 U.S. stocks, while the Russell 2000® specifically focuses on small-cap stocks, influencing many investment strategies and index funds.